Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk shares have fallen more than 66% from their 2024 high, leaving the stock at a 4.0x price-to-sales ratio and 11.6x P/E, versus five-year averages of 8.6x and 25.1x, respectively. The company offers a 3.7% dividend yield with a payout ratio below 40%, but faces material execution risk as it attempts to regain GLP-1 market share from Eli Lilly through its Wegovy pill and lower-price, volume-led strategy. Near-term revenue and earnings are under pressure from price cuts, although the article views the long-term risk/reward as favorable at the current valuation.

Analysis

NVO's apparent value is not a conventional mean-reversion setup: the relevant debate is whether lower realized net price can unlock enough treated-patient growth to stabilize absolute GLP-1 gross profit. If volume growth merely offsets price concessions, consensus EPS estimates can continue stepping down and the low headline P/E is a value trap. Conversely, incremental manufacturing utilization and direct-to-consumer oral adoption could create operating leverage once demand shifts from supply-constrained to access-constrained.

LLY's competitive advantage is likely more durable than current relative valuations imply because prescriber inertia, payer formulary placement, and superior real-world persistence reinforce scale. The first-order risk to LLY is not NVO reclaiming leadership, but category pricing becoming the competitive variable; that would pressure the market's premium multiple even if LLY retains unit share. Pharmacy-benefit-manager negotiations and employer coverage decisions over the next 1-3 months matter more than early prescription commentary.

The contrarian opportunity is that NVO does not need to win share for the equity to work: maintaining a profitable second position in an expanding obesity market could support a substantial rerating if guidance stops falling. But the 6-18 month structural risk is that oral formulations lower barriers to entry, shifting the category toward branded-price competition before next-generation efficacy compounds fully differentiate. Treat company-reported early pill uptake cautiously until refill persistence, net price, and formulary access are disclosed.

Falsification for a tactical NVO recovery is another cut to full-year operating-profit guidance or evidence that incremental prescriptions require accelerating rebates. For LLY, a meaningful narrowing of prescription share combined with deteriorating net pricing—not isolated launch data—would challenge the premium-growth thesis.

Key Decisions for Investors

• Maintain LLY over NVO as a 1-3 month relative-value pair; size long LLY/short NVO beta-neutral only after checking current prescription-share and consensus-revision trends. Target a 10-15% relative move; exit if NVO share gains persist for two monthly datasets while LLY net-price assumptions weaken.
• Do not initiate outright NVO solely on trailing valuation. Place an earnings-watch alert: consider a 6-12 month long only if management reiterates operating-profit guidance and reports volume growth exceeding net-price declines, implying positive GLP-1 revenue growth rather than share purchased through discounting.
• For existing LLY longs, hedge 6-12 month category-pricing risk with limited-risk put spreads around the next major payer/formulary decision or earnings event. The key downside trigger is a reduction in revenue guidance attributable to realized price rather than supply capacity.
• Avoid extrapolating the article's NFLX and NVDA references into a trade; they have no fundamental transmission channel to obesity-drug economics.